Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

4D Molecular Therapeutics Inc (FDMT)

4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,189,400
  • Shares Outstanding, K 51,157
  • Annual Sales, $ 20,720 K
  • Annual Income, $ -100,840 K
  • 60-Month Beta 2.87
  • Price/Sales 58.09
  • Price/Cash Flow N/A
  • Price/Book 3.27
Trade FDMT with:

Options Overview Details

View History
  • Implied Volatility 79.55% ( +0.73%)
  • Historical Volatility 65.79%
  • IV Percentile 59%
  • IV Rank 21.07%
  • IV High 196.67% on 01/26/24
  • IV Low 48.29% on 11/14/23
  • Put/Call Vol Ratio 0.50
  • Today's Volume 3
  • Volume Avg (30-Day) 84
  • Put/Call OI Ratio 0.55
  • Today's Open Interest 9,849
  • Open Int (30-Day) 10,852

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.73
  • Number of Estimates 4
  • High Estimate -0.68
  • Low Estimate -0.79
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +17.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.75 +2.20%
on 04/26/24
36.25 -35.86%
on 03/27/24
-10.80 (-31.72%)
since 03/26/24
3-Month
16.76 +38.68%
on 02/01/24
36.25 -35.86%
on 03/27/24
+5.75 (+32.86%)
since 01/26/24
52-Week
9.44 +146.29%
on 10/17/23
36.25 -35.86%
on 03/27/24
+2.68 (+13.03%)
since 04/26/23

Most Recent Stories

More News
Markets Today: Stocks Slip on Hawkish Fed Comments

Morning Markets March E-Mini S&P 500 futures (ESH24 ) are down -0.30%, and March Nasdaq 100 E-Mini futures (NQH24 ) are down -0.19%. Stock index futures this morning are mildly lower as higher bond yields...

ESM24 : 5,144.50 (+0.25%)
NQM24 : 17,906.75 (+0.34%)
BA : 167.22 (+0.25%)
APD : 236.08 (+0.43%)
ZS : 177.05 (+1.28%)
MAT : 18.36 (-0.60%)
CYTK : 65.34 (+0.83%)
GWW : 929.26 (-1.96%)
CAT : 343.38 (+1.59%)
EL : 147.45 (+1.70%)
FDMT : 23.25 (-1.19%)
CTLT : 55.92 (+0.22%)
Stocks Set to Open Lower as Investors Weigh Powell’s Remarks, Earnings and Fed Speak in Focus

March S&P 500 E-Mini futures (ESH24) are down -0.24%, and March Nasdaq 100 E-Mini futures (NQH24) are down -0.12% this morning as U.S. Treasury yields climbed on relatively hawkish comments from Federal...

ESH24 : 5,101.67s (-1.01%)
NQH24 : 17,854.75s (-0.94%)
META : 443.29 (+0.43%)
EW : 86.43 (-1.80%)
AMZN : 179.62 (+3.43%)
CHTR : 254.61 (-1.73%)
MCD : 273.09 (-0.91%)
CAT : 343.38 (+1.59%)
LLY : 733.51 (+1.19%)
F : 12.79 (-1.92%)
AMGN : 269.98 (+0.22%)
DIS : 112.73 (-0.04%)
Astellas and 4D Molecular Therapeutics (4DMT) Enter into License Agreement to Use 4DMT's Proprietary Intravitreal R100 Vector for Rare Ophthalmic Targets

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) (President and CEO: Naoki Okamura, "Astellas") and 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) (CEO: David...

FDMT : 23.25 (-1.19%)
Markets Today: Stocks Higher as Bond Yields Fall on Jobless Claims Surge

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.03%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.16%. U.S. stock index futures this morning recovered from overnight...

ESM24 : 5,144.50 (+0.25%)
NQM24 : 17,906.75 (+0.34%)
SMTC : 35.77 (+3.08%)
ADBE : 477.56 (+0.87%)
ALV : 122.29 (+5.56%)
IGT : 20.30 (+0.20%)
REVG : 21.24 (-2.34%)
TCOM : 50.60 (+0.36%)
FDMT : 23.25 (-1.19%)
SIG : 101.80 (+2.15%)
OXM : 106.71 (+0.91%)
SMAR : 38.28 (+0.53%)
Stocks Little Changed Before the Open as Investors Weigh Interest Rate Outlook

June S&P 500 futures (ESM23) are up +0.05%, and June Nasdaq 100 E-Mini futures (NQM23) are up +0.15% this morning after three major U.S. benchmark indices finished the regular session mixed as an unexpected...

ESM23 : 4,453.35s (+0.61%)
NQM23 : 15,316.61s (+0.85%)
CPB : 44.85 (-1.15%)
MCHP : 93.60 (+1.51%)
NXPI : 242.70 (+1.94%)
WBD : 8.11 (-2.17%)
WIZZ.LN : 2,170.000 (-1.27%)
GME : 11.90 (+6.16%)
HCP : 32.59 (-0.70%)
EXPI : 10.12 (+1.50%)
CURV : 5.00 (+1.63%)
FDMT : 23.25 (-1.19%)
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of 0% and 79.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

FDMT : 23.25 (-1.19%)
MRNS : 1.4050 (-1.06%)
Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates

Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 60% and 27.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

SPPI : 1.0300 (unch)
FDMT : 23.25 (-1.19%)
4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?

4D Molecular Therapeutics, Inc. (FDMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further...

FDMT : 23.25 (-1.19%)
NOTV : 4.05 (-5.59%)
4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock?

4D Molecular Therapeutics, Inc. (FDMT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further...

FDMT : 23.25 (-1.19%)
TBPH : 9.12 (-0.22%)
4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the...

FDMT : 23.25 (-1.19%)
BVS : 3.98 (-2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas....

See More

Key Turning Points

3rd Resistance Point 24.92
2nd Resistance Point 24.39
1st Resistance Point 23.82
Last Price 23.25
1st Support Level 22.72
2nd Support Level 22.18
3rd Support Level 21.61

See More

52-Week High 36.25
Fibonacci 61.8% 26.01
Last Price 23.25
Fibonacci 50% 22.84
Fibonacci 38.2% 19.68
52-Week Low 9.44

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar